Recombinant AAV Helper Polynucleotides for Higher Large-Scale Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved methods to enhance the productivity and yield of large-scale production of recombinant adeno-associated virus (rAAV) particles for gene therapy applications, as current methods are limited by the lack of efficient production techniques.
Innovation Solution
The use of recombinant polynucleotides encoding adenovirus E2A DNA binding protein (DBP), E4 ORF6 and ORF7 polypeptide, and adenovirus VA RNA I, without the inclusion of adenovirus ITR sequence, L3 23K endoprotease, L5 pVI/fibre, and L4 pVIII/hexon-associated precursor, to facilitate the production of rAAV particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used for large-scale production of rAAV particles, then production capacity is maintained at current levels, but productivity and yield are limited
Solution Approach 1:
The patent modifies the genetic parameters of the production system by introducing recombinant polynucleotides encoding adenovirus E2A DBP, E4 ORF6/ORF7, and VA RNA I, which change the biochemical parameters of the viral replication process to achieve higher rAAV yield and production efficiency
Solution Approach 2:
The patent uses recombinant polynucleotides as intermediary elements that facilitate the production process by providing helper functions (E2A DBP, E4 ORF6/ORF7, VA RNA I) that mediate between the host cell and the rAAV particle assembly, enabling efficient packaging without including unnecessary viral genes
Data Source
AI summary
Provided herein are recombinant polynucleotides encoding helper functions and helper plasmids suitable for use in the production of recombinant AAV particles. Also provided herein are methods for producing rAAV particles.